Published in Clinical Oncology Week, May 16th, 2005
Researchers also report that the regimen was well tolerated.
For this prospective study, "vinorelbine 25 mg/m2 30-minute intravenous infusion, and high-dose 5-FU 2600 mg/m2 plus LV 300 mg/m2 24-hour intravenous infusion (HDFL regimen) were given on days 1 and 8 every 3 weeks."
K.H. Yeh and colleagues, National Taiwan University Hospital, reported, "Between June 1999 and April 2003, 40 patients with histologically...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.